Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| BIODELIVERY SCIENCES INTERNATIONAL INCBDSI · Entity 128876 | SVP & Chief Technology Officer | March 24, 2017 | March 24, 2017 |
| Inhibitor Therapeutics, Inc.INTI · Entity 7783 | Director | May 05, 2026 | June 01, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
BIODELIVERY SCIENCES INTERNATIONAL INC
Report date March 24, 2017 · Filed March 24, 2017
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 272,413 |
Ending reported balance
After 2017-03-23 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2017-03-22 · Grant · Acquired 1,474 · Balance 272,943 F1: The shares of common stock reported on this Form 4 were acquired by the Reporting Person in connection with the vesting of Restricted Stock Units ("RSUs") granted to the Reporting Person under the Issuer's Long Term Incentive Plan. Row 2 · 2017-03-23 · Sale · Disposed 530 · Balance 272,413 F2: The shares of common stock were sold under a pre-planned 10b5-1 trading plan and were sold to cover the Reporting Person's tax liability upon the vesting of RSUs. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 · Expires 2017-03-22 | Direct | 0 |
Reported balance
After 2017-03-22 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2017-03-22 · Grant · Acquired 1,474 · Balance 0 F1: The shares of common stock reported on this Form 4 were acquired by the Reporting Person in connection with the vesting of Restricted Stock Units ("RSUs") granted to the Reporting Person under the Issuer's Long Term Incentive Plan. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares of common stock reported on this Form 4 were acquired by the Reporting Person in connection with the vesting of Restricted Stock Units ("RSUs") granted to the Reporting Person under the Issuer's Long Term Incentive Plan.
F2: The shares of common stock were sold under a pre-planned 10b5-1 trading plan and were sold to cover the Reporting Person's tax liability upon the vesting of RSUs.
Inhibitor Therapeutics, Inc.
Report date May 05, 2026 · Filed June 01, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 200,000 |
Reported balance
After 2026-05-05 transaction · row 1
1 source rowRow 1 · 2026-05-05 · Grant · Acquired 50,000 · Balance 200,000 F1: Represents restricted common stock issued to the Reporting Person as compensation pursuant to the Issuer's 2025 Equity Incentive Plan. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents restricted common stock issued to the Reporting Person as compensation pursuant to the Issuer's 2025 Equity Incentive Plan.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 05, 2026 Filed Jun 1, 2026 20:15 UTC | Inhibitor Therapeutics, Inc. INTI · Entity 7783 | GrantCommon Stock | 50,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001493152-26-026623 · ownership.xml · nonDerivative · entry 1 Vasisht Niraj · CIK 0001662930 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 200,000 F1 · shares: Represents restricted common stock issued to the Reporting Person as compensation pursuant to the Issuer's 2025 Equity Incentive Plan. Read SEC document |
| April 01, 2025 Filed Apr 10, 2025 17:30 UTC | Inhibitor Therapeutics, Inc. INTI · Entity 7783 | GrantCommon Stock | 50,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001641172-25-003556 · ownership.xml · nonDerivative · entry 1 Vasisht Niraj · CIK 0001662930 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: Not disclosed F1 · shares: Represents restricted common stock issued to the Reporting Person as compensation pursuant to the Issuer's 2014 Equity Incentive Plan. Read SEC document |
| March 23, 2017 Filed Mar 24, 2017 18:07 UTC | BIODELIVERY SCIENCES INTERNATIONAL INC BDSI · Entity 128876 | SaleCommon Stock | 530 | $1.90 | $1,007.00 |
DisclosureSEC source: 0000899243-17-008553 · doc4.xml · nonDerivative · entry 2 Vasisht Niraj · CIK 0001662930 · SVP & Chief Technology Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 272,413 F2 · kind: The shares of common stock were sold under a pre-planned 10b5-1 trading plan and were sold to cover the Reporting Person's tax liability upon the vesting of RSUs. Read SEC document |
| March 22, 2017 Filed Mar 24, 2017 18:07 UTC | BIODELIVERY SCIENCES INTERNATIONAL INC BDSI · Entity 128876 | GrantRestricted Stock Units · Derivative | 1,474 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0000899243-17-008553 · doc4.xml · derivative · entry 3 Vasisht Niraj · CIK 0001662930 · SVP & Chief Technology Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,474 shares Expires 2017-03-22 F1 · kind: The shares of common stock reported on this Form 4 were acquired by the Reporting Person in connection with the vesting of Restricted Stock Units ("RSUs") granted to the Reporting Person under the Issuer's Long Term Incentive Plan. Read SEC document |
| March 22, 2017 Filed Mar 24, 2017 18:07 UTC | BIODELIVERY SCIENCES INTERNATIONAL INC BDSI · Entity 128876 | GrantCommon Stock | 1,474 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-17-008553 · doc4.xml · nonDerivative · entry 1 Vasisht Niraj · CIK 0001662930 · SVP & Chief Technology Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 272,943 F1 · price: The shares of common stock reported on this Form 4 were acquired by the Reporting Person in connection with the vesting of Restricted Stock Units ("RSUs") granted to the Reporting Person under the Issuer's Long Term Incentive Plan. Read SEC document |
| March 01, 2017 Filed Mar 3, 2017 19:19 UTC | BIODELIVERY SCIENCES INTERNATIONAL INC BDSI · Entity 128876 | Exercise / conversionRestricted Stock Units · Derivative | 50,000 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0000899243-17-006500 · doc4.xml · derivative · entry 9 Vasisht Niraj · CIK 0001662930 · SVP & Chief Technology Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 50,000 shares Expires 2019-03-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · kind: The shares of common stock were acquired by the Reporting Person as a result of the vesting of one-third of the RSUs granted to the Reporting Person on February 29, 2016 under the Plan. The remainder of the RSUs under this grant will vest in equal installments on March 1, 2018 and March 1, 2019. Read SEC document |
| March 01, 2017 Filed Mar 3, 2017 19:19 UTC | BIODELIVERY SCIENCES INTERNATIONAL INC BDSI · Entity 128876 | SaleCommon Stock | 9,000 | $2.03 | $18,270.00 |
DisclosureSEC source: 0000899243-17-006500 · doc4.xml · nonDerivative · entry 6 Vasisht Niraj · CIK 0001662930 · SVP & Chief Technology Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 271,469 F2 · kind: The shares of common stock were sold upon expiration of a pre-planned 10b5-1 trading plan, and were sold to cover the Reporting Person's additional tax liability upon the vesting of the RSUs. F7 · price: On March 1, 2017, the Reporting Person sold an aggregate of 9,000 shares of the Issuer's Common Stock at a weighted average price of $2.03 per share. The highest sale price for the Common Stock was $2.05 per share and the lowest sale price was $2.00 per share. The Reporting Person undertakes to provide the Company, any security holder of the Company or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| March 01, 2017 Filed Mar 3, 2017 19:19 UTC | BIODELIVERY SCIENCES INTERNATIONAL INC BDSI · Entity 128876 | Exercise / conversionCommon Stock | 50,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-17-006500 · doc4.xml · nonDerivative · entry 5 Vasisht Niraj · CIK 0001662930 · SVP & Chief Technology Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 280,469 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · kind: The shares of common stock were acquired by the Reporting Person as a result of the vesting of one-third of the RSUs granted to the Reporting Person on February 29, 2016 under the Plan. The remainder of the RSUs under this grant will vest in equal installments on March 1, 2018 and March 1, 2019. F6 · price: The shares of common stock were acquired by the Reporting Person as a result of the vesting of one-third of the RSUs granted to the Reporting Person on February 29, 2016 under the Plan. The remainder of the RSUs under this grant will vest in equal installments on March 1, 2018 and March 1, 2019. Read SEC document |
| February 23, 2017 Filed Mar 3, 2017 19:19 UTC | BIODELIVERY SCIENCES INTERNATIONAL INC BDSI · Entity 128876 | Exercise / conversionRestricted Stock Units · Derivative | 66,667 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0000899243-17-006500 · doc4.xml · derivative · entry 8 Vasisht Niraj · CIK 0001662930 · SVP & Chief Technology Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 66,666 Underlying: Common Stock · 66,667 shares Expires 2018-02-23 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · kind: The shares of common stock were acquired by the Reporting Person as a result of the vesting of one-third of the RSUs granted to the Reporting Person on February 23, 2015 under the Plan. The remainder of the RSUs under this grant will vest on February 23, 2018. Read SEC document |
| February 23, 2017 Filed Mar 3, 2017 19:19 UTC | BIODELIVERY SCIENCES INTERNATIONAL INC BDSI · Entity 128876 | SaleCommon Stock | 23,500 | $1.95 | $45,825.00 |
DisclosureSEC source: 0000899243-17-006500 · doc4.xml · nonDerivative · entry 4 Vasisht Niraj · CIK 0001662930 · SVP & Chief Technology Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 230,469 F2 · kind: The shares of common stock were sold upon expiration of a pre-planned 10b5-1 trading plan, and were sold to cover the Reporting Person's additional tax liability upon the vesting of the RSUs. F5 · price: On February 23, 2017, the Reporting Person sold an aggregate of 23,500 shares of the Issuer's Common Stock at a weighted average price of $1.95 per share. The highest sale price for the Common Stock was $2.05 per share and the lowest sale price was $1.90 per share. The Reporting Person undertakes to provide the Company, any security holder of the Company or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| February 23, 2017 Filed Mar 3, 2017 19:19 UTC | BIODELIVERY SCIENCES INTERNATIONAL INC BDSI · Entity 128876 | Exercise / conversionCommon Stock | 66,667 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-17-006500 · doc4.xml · nonDerivative · entry 3 Vasisht Niraj · CIK 0001662930 · SVP & Chief Technology Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 253,969 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · kind: The shares of common stock were acquired by the Reporting Person as a result of the vesting of one-third of the RSUs granted to the Reporting Person on February 23, 2015 under the Plan. The remainder of the RSUs under this grant will vest on February 23, 2018. F4 · price: The shares of common stock were acquired by the Reporting Person as a result of the vesting of one-third of the RSUs granted to the Reporting Person on February 23, 2015 under the Plan. The remainder of the RSUs under this grant will vest on February 23, 2018. Read SEC document |
| February 22, 2017 Filed Mar 3, 2017 19:19 UTC | BIODELIVERY SCIENCES INTERNATIONAL INC BDSI · Entity 128876 | Exercise / conversionRestricted Stock Units · Derivative | 24,980 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0000899243-17-006500 · doc4.xml · derivative · entry 7 Vasisht Niraj · CIK 0001662930 · SVP & Chief Technology Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 24,980 shares Expires 2017-02-22 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The shares of common stock were acquired by the Reporting Person as a result of the vesting of the remaining RSUs that had been granted to the Reporting Person on February 22, 2014 under the Issuer's 2011 Equity Incentive Plan, as amended (the "Plan"). Read SEC document |
| February 22, 2017 Filed Mar 3, 2017 19:19 UTC | BIODELIVERY SCIENCES INTERNATIONAL INC BDSI · Entity 128876 | SaleCommon Stock | 9,500 | $2.01 | $19,095.00 |
DisclosureSEC source: 0000899243-17-006500 · doc4.xml · nonDerivative · entry 2 Vasisht Niraj · CIK 0001662930 · SVP & Chief Technology Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 187,302 F2 · kind: The shares of common stock were sold upon expiration of a pre-planned 10b5-1 trading plan, and were sold to cover the Reporting Person's additional tax liability upon the vesting of the RSUs. F3 · price: On February 22, 2017, the Reporting Person sold an aggregate of 9,500 shares of the Issuer's Common Stock at a weighted average price of $2.01 per share. The highest sale price for the Common Stock was $2.06 per share and the lowest sale price was $1.96 per share. The Reporting Person undertakes to provide the Company, any security holder of the Company or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| February 22, 2017 Filed Mar 3, 2017 19:19 UTC | BIODELIVERY SCIENCES INTERNATIONAL INC BDSI · Entity 128876 | Exercise / conversionCommon Stock | 24,980 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-17-006500 · doc4.xml · nonDerivative · entry 1 Vasisht Niraj · CIK 0001662930 · SVP & Chief Technology Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 196,802 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The shares of common stock were acquired by the Reporting Person as a result of the vesting of the remaining RSUs that had been granted to the Reporting Person on February 22, 2014 under the Issuer's 2011 Equity Incentive Plan, as amended (the "Plan"). F1 · price: The shares of common stock were acquired by the Reporting Person as a result of the vesting of the remaining RSUs that had been granted to the Reporting Person on February 22, 2014 under the Issuer's 2011 Equity Incentive Plan, as amended (the "Plan"). Read SEC document |
| February 06, 2017 Filed Feb 8, 2017 18:00 UTC | BIODELIVERY SCIENCES INTERNATIONAL INC BDSI · Entity 128876 | GrantRestricted Stock Units · Derivative | 162,500 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0000899243-17-003152 · doc4.xml · derivative · entry 4 Vasisht Niraj · CIK 0001662930 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 162,500 Underlying: Common Stock · 162,500 shares Expires 2020-03-18 F4 · kind: The RSUs were issued to the Reporting Person on February 6, 2017, pursuant to a grant under the Plan. The award is subject to time-based vesting and will vest as follows: (i) one-third vests on the later to occur of March 1, 2018 or the first open trading window of 2018; (ii) one-third vests on the date of the first open trading window of 2019; and (iii) the remaining third vests on the first open trading window of 2020. Upon vesting, each RSU entitles the Reporting Person to one share of the Issuer's common stock. The Reporting Person has been granted the right to elect to defer actual payment of a vested RSU award, subject to compliance with Internal Revenue Code Section 409A. The issuance of these RSUs is subject to shareholder approval at the 2017 Annual Meeting of Stockholders. F4 · derivative.exercise_date: The RSUs were issued to the Reporting Person on February 6, 2017, pursuant to a grant under the Plan. The award is subject to time-based vesting and will vest as follows: (i) one-third vests on the later to occur of March 1, 2018 or the first open trading window of 2018; (ii) one-third vests on the date of the first open trading window of 2019; and (iii) the remaining third vests on the first open trading window of 2020. Upon vesting, each RSU entitles the Reporting Person to one share of the Issuer's common stock. The Reporting Person has been granted the right to elect to defer actual payment of a vested RSU award, subject to compliance with Internal Revenue Code Section 409A. The issuance of these RSUs is subject to shareholder approval at the 2017 Annual Meeting of Stockholders. Read SEC document |
| January 30, 2017 Filed Feb 8, 2017 18:00 UTC | BIODELIVERY SCIENCES INTERNATIONAL INC BDSI · Entity 128876 | Exercise / conversionRestricted Stock Units · Derivative | 16,666 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0000899243-17-003152 · doc4.xml · derivative · entry 3 Vasisht Niraj · CIK 0001662930 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 16,666 shares Expires 2017-01-30 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The shares of common stock were acquired by the Reporting Person as a result of the vesting of the remaining RSUs that had been granted to the Reporting Person on January 30, 2014 under the Issuer's 2011 Equity Incentive Plan, as amended (the "Plan"). Read SEC document |
| January 30, 2017 Filed Feb 8, 2017 18:00 UTC | BIODELIVERY SCIENCES INTERNATIONAL INC BDSI · Entity 128876 | SaleCommon Stock | 6,905 | $1.91 | $13,188.55 |
DisclosureSEC source: 0000899243-17-003152 · doc4.xml · nonDerivative · entry 2 Vasisht Niraj · CIK 0001662930 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 171,822 F2 · kind: The shares of common stock were sold upon expiration of a pre-planned 10b5-1 trading plan, and were sold to cover the Reporting Person's additional tax liability upon the vesting of the RSUs. F3 · price: On January 30, 2017, the Reporting Person sold an aggregate of 6,905 shares of the Issuer's Common Stock at a weighted average price of $1.91 per share. The highest sale price for the Common Stock was $1.95 per share and the lowest sale price was $1.90 per share. The Reporting Person undertakes to provide the Company, any security holder of the Company or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| January 30, 2017 Filed Feb 8, 2017 18:00 UTC | BIODELIVERY SCIENCES INTERNATIONAL INC BDSI · Entity 128876 | Exercise / conversionCommon Stock | 16,666 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-17-003152 · doc4.xml · nonDerivative · entry 1 Vasisht Niraj · CIK 0001662930 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 178,727 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The shares of common stock were acquired by the Reporting Person as a result of the vesting of the remaining RSUs that had been granted to the Reporting Person on January 30, 2014 under the Issuer's 2011 Equity Incentive Plan, as amended (the "Plan"). F1 · price: The shares of common stock were acquired by the Reporting Person as a result of the vesting of the remaining RSUs that had been granted to the Reporting Person on January 30, 2014 under the Issuer's 2011 Equity Incentive Plan, as amended (the "Plan"). Read SEC document |
| September 23, 2016 Filed Sep 23, 2016 18:30 UTC | BIODELIVERY SCIENCES INTERNATIONAL INC BDSI · Entity 128876 | SaleCommon Stock | 7,000 | $2.68 | $18,760.00 |
DisclosureSEC source: 0000899243-16-029936 · doc4.xml · nonDerivative · entry 7 Vasisht Niraj · CIK 0001662930 · Chief Technology Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 162,061 F8 · kind: The shares of common stock were sold upon expiration of a pre-planned 10b5-1 trading plan, and were sold to cover the Reporting Person's additional tax liability upon the vesting of RSUs. F9 · price: On September 23, 2016, the Reporting Person sold an aggregate of 7,000 shares of the Issuer's Common Stock at a weighted average price of $2.68 per share. The highest sale price for the Common Stock was $2.81 per share and the lowest sale price was $2.58 per share. The Reporting Person undertakes to provide the Company, any security holder of the Company or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| September 21, 2016 Filed Sep 23, 2016 18:30 UTC | BIODELIVERY SCIENCES INTERNATIONAL INC BDSI · Entity 128876 | Exercise / conversionRestricted Stock Units · Derivative | 66,667 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0000899243-16-029936 · doc4.xml · derivative · entry 11 Vasisht Niraj · CIK 0001662930 · Chief Technology Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 133,333 Underlying: Common Stock · 66,667 shares Expires 2018-02-23 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · kind: The shares of common stock were acquired by the Reporting Person as a result of the vesting of one-third of the RSUs granted to the Reporting Person on February 23, 2015 under the Plan. Pursuant to a deferral, these RSUs vested on September 21, 2016. The remainder of the RSUs under this grant will vest in equal portions on each of (i) February 23, 2017 and (ii) February 23, 2018. Read SEC document |
| September 21, 2016 Filed Sep 23, 2016 18:30 UTC | BIODELIVERY SCIENCES INTERNATIONAL INC BDSI · Entity 128876 | Exercise / conversionRestricted Stock Units · Derivative | 24,980 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0000899243-16-029936 · doc4.xml · derivative · entry 10 Vasisht Niraj · CIK 0001662930 · Chief Technology Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,980 Underlying: Common Stock · 24,980 shares Expires 2017-02-22 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · kind: The shares of common stock were acquired by the Reporting Person as a result of the vesting of one-half of the RSUs granted to the Reporting Person on February 22, 2014 under the Plan. Pursuant to a deferral, these RSUs vested on September 21, 2016. The remaining half of the RSUs under this grant will vest on February 22, 2017. Read SEC document |
| September 21, 2016 Filed Sep 23, 2016 18:30 UTC | BIODELIVERY SCIENCES INTERNATIONAL INC BDSI · Entity 128876 | Exercise / conversionRestricted Stock Units · Derivative | 16,667 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0000899243-16-029936 · doc4.xml · derivative · entry 9 Vasisht Niraj · CIK 0001662930 · Chief Technology Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,666 Underlying: Common Stock · 16,667 shares Expires 2017-01-30 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · kind: The shares of common stock were acquired by the Reporting Person as a result of the vesting of one-half of the RSUs granted to the Reporting Person on January 30, 2014 under the Plan. Pursuant to a deferral, these RSUs vested on September 21, 2016. The remaining half of the RSUs under this grant will vest on January 30, 2017. Read SEC document |
| September 21, 2016 Filed Sep 23, 2016 18:30 UTC | BIODELIVERY SCIENCES INTERNATIONAL INC BDSI · Entity 128876 | Exercise / conversionRestricted Stock Units · Derivative | 27,666 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0000899243-16-029936 · doc4.xml · derivative · entry 8 Vasisht Niraj · CIK 0001662930 · Chief Technology Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 27,666 shares Expires 2016-09-21 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · kind: The shares of common stock were acquired by the Reporting Person as a result of the vesting of 27,666 RSUs granted to the Reporting Person on February 20, 2013 under the Issuer's 2011 Equity Incentive Plan, as amended (the "Plan"). Pursuant to a deferral, these RSUs vested on September 21, 2016. Read SEC document |
| September 21, 2016 Filed Sep 23, 2016 18:30 UTC | BIODELIVERY SCIENCES INTERNATIONAL INC BDSI · Entity 128876 | SaleCommon Stock | 40,000 | $2.39 | $95,600.00 |
DisclosureSEC source: 0000899243-16-029936 · doc4.xml · nonDerivative · entry 6 Vasisht Niraj · CIK 0001662930 · Chief Technology Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 169,061 F6 · kind: The shares of common stock were sold under a pre-planned 10b5-1 trading plan and were sold to cover the Reporting Person's tax liability upon the vesting of RSUs. F7 · price: On September 21, 2016, the Reporting Person sold an aggregate of 40,000 shares of the Issuer's Common Stock at a weighted average price of $2.39 per share. The highest sale price for the Common Stock was $2.45 per share and the lowest sale price was $2.35 per share. The Reporting Person undertakes to provide the Company, any security holder of the Company or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| September 21, 2016 Filed Sep 23, 2016 18:30 UTC | BIODELIVERY SCIENCES INTERNATIONAL INC BDSI · Entity 128876 | Exercise / conversionCommon Stock | 66,667 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-16-029936 · doc4.xml · nonDerivative · entry 5 Vasisht Niraj · CIK 0001662930 · Chief Technology Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 209,061 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · kind: The shares of common stock were acquired by the Reporting Person as a result of the vesting of one-third of the RSUs granted to the Reporting Person on February 23, 2015 under the Plan. Pursuant to a deferral, these RSUs vested on September 21, 2016. The remainder of the RSUs under this grant will vest in equal portions on each of (i) February 23, 2017 and (ii) February 23, 2018. F5 · price: The shares of common stock were acquired by the Reporting Person as a result of the vesting of one-third of the RSUs granted to the Reporting Person on February 23, 2015 under the Plan. Pursuant to a deferral, these RSUs vested on September 21, 2016. The remainder of the RSUs under this grant will vest in equal portions on each of (i) February 23, 2017 and (ii) February 23, 2018. Read SEC document |
| September 21, 2016 Filed Sep 23, 2016 18:30 UTC | BIODELIVERY SCIENCES INTERNATIONAL INC BDSI · Entity 128876 | Exercise / conversionCommon Stock | 24,980 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-16-029936 · doc4.xml · nonDerivative · entry 4 Vasisht Niraj · CIK 0001662930 · Chief Technology Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 142,394 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · kind: The shares of common stock were acquired by the Reporting Person as a result of the vesting of one-half of the RSUs granted to the Reporting Person on February 22, 2014 under the Plan. Pursuant to a deferral, these RSUs vested on September 21, 2016. The remaining half of the RSUs under this grant will vest on February 22, 2017. F4 · price: The shares of common stock were acquired by the Reporting Person as a result of the vesting of one-half of the RSUs granted to the Reporting Person on February 22, 2014 under the Plan. Pursuant to a deferral, these RSUs vested on September 21, 2016. The remaining half of the RSUs under this grant will vest on February 22, 2017. Read SEC document |
| September 21, 2016 Filed Sep 23, 2016 18:30 UTC | BIODELIVERY SCIENCES INTERNATIONAL INC BDSI · Entity 128876 | Exercise / conversionCommon Stock | 16,667 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-16-029936 · doc4.xml · nonDerivative · entry 3 Vasisht Niraj · CIK 0001662930 · Chief Technology Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 117,414 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · kind: The shares of common stock were acquired by the Reporting Person as a result of the vesting of one-half of the RSUs granted to the Reporting Person on January 30, 2014 under the Plan. Pursuant to a deferral, these RSUs vested on September 21, 2016. The remaining half of the RSUs under this grant will vest on January 30, 2017. F3 · price: The shares of common stock were acquired by the Reporting Person as a result of the vesting of one-half of the RSUs granted to the Reporting Person on January 30, 2014 under the Plan. Pursuant to a deferral, these RSUs vested on September 21, 2016. The remaining half of the RSUs under this grant will vest on January 30, 2017. Read SEC document |
| September 21, 2016 Filed Sep 23, 2016 18:30 UTC | BIODELIVERY SCIENCES INTERNATIONAL INC BDSI · Entity 128876 | Exercise / conversionCommon Stock | 27,666 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-16-029936 · doc4.xml · nonDerivative · entry 2 Vasisht Niraj · CIK 0001662930 · Chief Technology Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,747 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · kind: The shares of common stock were acquired by the Reporting Person as a result of the vesting of 27,666 RSUs granted to the Reporting Person on February 20, 2013 under the Issuer's 2011 Equity Incentive Plan, as amended (the "Plan"). Pursuant to a deferral, these RSUs vested on September 21, 2016. F2 · price: The shares of common stock were acquired by the Reporting Person as a result of the vesting of 27,666 RSUs granted to the Reporting Person on February 20, 2013 under the Issuer's 2011 Equity Incentive Plan, as amended (the "Plan"). Pursuant to a deferral, these RSUs vested on September 21, 2016. Read SEC document |
| September 21, 2016 Filed Sep 23, 2016 18:30 UTC | BIODELIVERY SCIENCES INTERNATIONAL INC BDSI · Entity 128876 | GrantCommon Stock | 4,661 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-16-029936 · doc4.xml · nonDerivative · entry 1 Vasisht Niraj · CIK 0001662930 · Chief Technology Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 73,081 F1 · price: The shares of common stock reported on this Form 4 were acquired by the Reporting Person in connection with the vesting of Restricted Stock Units ("RSUs") granted to the Reporting Person under the Issuer's Long Term Incentive Plan. Pursuant to a deferral, these RSUs vested on September 21, 2016. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.